Dupilumab – July 2026

  • Brand names:
    • Dupixent®
  • Pharmaceutical Company:
    • SANOFI-AVENTIS AUSTRALIA PTY LTD
  • Condition/Indication: Chronic severe atopic dermatitis
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026